馬應龍(600993.SH):巴柳氮鈉膠囊獲藥品補充申請批件
格隆匯11月19日丨馬應龍(600993.SH)公佈,近日,公司收到國家藥品監督管理局頒發的關於巴柳氮鈉膠囊的《藥品補充申請批件》,該藥品通過技術轉讓補充申請。
巴柳氮鈉膠囊主要用於輕度至中度活動性潰瘍性結腸炎的治療,其主要成分為巴柳氮鈉。巴柳氮鈉是新型5-氨基水楊酸類前體藥物,該藥口服後以原形進入結腸,在結腸細菌酶的作用下,偶氮鍵斷裂,在炎症部位釋出美沙拉嗪,能保證藥物更好到達結腸部位發揮治療作用,具有起效快、療效好、不良反應少等特點,在氨基水楊酸類治療藥物中顯示出明顯治療優勢,具有很高的臨牀應用價值。
潰瘍性結腸炎是最主要的兩種炎症性腸病之一,根據《炎症性腸病全球負擔指數2015~2025》,2016年國內炎症性腸病藥物銷售額約為50億元,預計2025年,中國將擁有超過150萬炎症性腸病患者,藥物市場為166億元。目前該藥品國內其他生產廠家共3家,分別為湖北百科亨迪藥業有限公司、山西振東安特生物製藥有限公司、赤峯蒙欣藥業有限公司。根據米內網數據顯示,該藥品2018年國內年度銷售收入1364萬元。
公司在2017年2月24日向國家藥監局提交技術轉讓補充申請,截至本公告日,該藥品項目技術轉讓及相關研究開發共計投入930.2萬元,其中技術轉讓費540.4萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.